- Expertise article
- MR Roof, E Vaughn, K Burkhart, W Johnson
Country: United States
Source: 2007 International Symposium of Emerging Diseases
Challenge strain(s): NADC, VR 2332, SDSU73, 17198-6, MN 184
Key points:
- The objective of this report was to summarize the data from 16 independent laboratory trials, which evaluated Ingelvac PRRS and Ingelvac ATP vaccine efficacy in the respiratory model.
- Vaccination was efficacious against a wide variety of heterologous challenge strains with varied isolation times, genetic sequences, and relative virulence.